Caroline Litchfield, EVP & CFO of Merck & Co Inc (MRK, Financial), sold 38,291 shares of the company on February 14, 2024, according to a recent SEC Filing. Merck & Co Inc is a global healthcare company that offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Over the past year, the insider has sold a total of 38,291 shares and has not made any purchases of the stock. The recent transaction reflects a continuation of this selling trend.
The insider transaction history for Merck & Co Inc shows a pattern of insider activity. There have been 19 insider sells and only 1 insider buy over the past year.
On the day of the insider's recent sale, shares of Merck & Co Inc were trading at $125.5, giving the company a market capitalization of $320,655.281 billion.
The stock's price-earnings ratio stands at 903.86, which is significantly above both the industry median of 22.37 and the company's historical median price-earnings ratio.
With a share price of $125.5 and a GuruFocus Value of $107.82, Merck & Co Inc has a price-to-GF-Value ratio of 1.16, indicating that the stock is considered Modestly Overvalued according to the GF Value metric.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
